drugset / Trial / NCT05088369
Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This will be a single centre, Phase 1, Placebo-controlled, Randomized, Doubleblind, SAD \& MAD Study to Assess the Safety, Tolerability and PK of HM201 in Healthy Subjects.
Timeline
- Start
- 2021-11-11
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM201 | Unknown | 0.01 mg/kg | Intravenous |
| Subject | HM201 | Unknown | 0.03 mg/kg | Intravenous |
| Subject | HM201 | Unknown | 0.06 mg/kg | Intravenous |
| Subject | HM201 | Unknown | 0.12 mg/kg | Intravenous |